Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 821Bacterial Cancer TherapyBacteriophages and microbial interactionsProbiotics and Fermented Foods

The DOI matches its Crossref record; 270 of the 271 references it cites were found in a registry or an index, and 1 are not checked yet.

Tumour-targeting bacteria engineered to fight cancer

Open access
Zhou, Shibin, Gravekamp, Claudia, Bermudes, David, Liu, Ke·2018·Nature Reviews Cancer

Abstract

Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, most late-stage cancers are either insensitive to the therapies to begin with or develop resistance later. Therapy with live tumour-targeting bacteria provides a unique option to meet these challenges. Compared with most other therapeutics, the effectiveness of tumour-targeting bacteria is not directly affected by the 'genetic makeup' of a tumour. Bacteria initiate their direct antitumour effects from deep within the tumour, followed by innate and adaptive antitumour immune responses. As microscopic 'robotic factories', bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents on the basis of clinical needs. Therapeutic approaches using live tumour-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumour regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumour-targeting bacteria, including a discussion of the regulatory issues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41568-018-0070-z

Cites

270 of 271 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 270 references

Cited by

See all 821

Metadata

Authors
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K.
Affiliations
  • Johns Hopkins University (US)
  • Albert Einstein College of Medicine (US)
  • California State University, Northridge (US)
  • Center for Biologics Evaluation and Research (US)
Corresponding author
Zhou, Shibin
Venue
Nature Reviews Cancer
Published
2018-11-07
Volume
18
Issue
12
Pages
727-743
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W2899862051
Cited by
821
References
270
Citations by year
2026: 94 · 2025: 159 · 2024: 141 · 2023: 142 · 2022: 128 · 2021: 81 · 2020: 49 · 2019: 25 · 2018: 1
FWCI
4.61
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature reviews. Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Yale University
  • Johns Hopkins University
  • National Cancer Institute (R21CA199010, P50CA062924)
  • National Institute of General Medical Sciences (SC3GM098207)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
  • Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
bacterial vectors, synthetic biology, bacterial engineering, antitumor immunity, tumor regression, combination cancer therapy, cancer immunotherapy, treatment resistance, clinical trials, regulatory challenges, bacterial safety
MeSH terms
Microorganisms, Genetically-Modified, Animals, Bacteria, Clostridium, Dogs, Genes, Synthetic, Genetic Vectors, Humans, Immunologic Factors, Listeria, Neoplasms, Plasmids, Prodrugs, Salmonella

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumour-targeting bacteria engineered to fight cancer. https://app.cochat.ai/papers/10.1038/s41568-018-0070-z
The paper
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018). Tumour-targeting bacteria engineered to fight cancer. Nature Reviews Cancer. https://doi.org/10.1038/s41568-018-0070-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.